• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Raising Pancreatic Cancer Awareness Through Patient Voices 

Raising Pancreatic Cancer Awareness Through Patient Voices 

by Elizabeth | Nov 26, 2024 | News

 With its Needle-Based Confocal Laser Endomicroscopy Solution, Mauna Kea is Playing a Decisive Role in the Fight Against Pancreatic Cancer  Paris and Boston, November 26, 2024 – 5:45 p.m. CET – This Pancreatic Cancer Awareness Month, Mauna Kea Technologies...
Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador 

Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador 

by Elizabeth | Nov 20, 2024 | News

Paris and Boston, November 20, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, is pleased to announce that Dr. Carlos...
Mauna Kea Technologies Announces Review of Strategic Alternatives 

Mauna Kea Technologies Announces Review of Strategic Alternatives 

by Elizabeth | Nov 19, 2024 | News

Paris and Boston, November 19, 2024 – 5:45 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that its Board of Directors,...
Dr. Som Krishna comments on pancreatic cancer awareness and early warning signs

Dr. Som Krishna comments on pancreatic cancer awareness and early warning signs

by Elizabeth | Nov 15, 2024 | Press Coverage

Dr. Som Krishna, Clinical Professor of Internal Medicine at The Ohio State University Wexner Medical Center, discusses how important it is to understand the early warning signs of pancreatic cancer, and the role that Cellvizio® can play. Watch the full interview...
Mauna Kea Technologies Announces Review of Strategic Alternatives 

Mauna Kea Technologies Provides an Update on Its Recent Developments

by Elizabeth | Nov 13, 2024 | News

Paris and Boston, November 13, 2024 – 12:15 p.m. CET – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, provides an update on its recent developments...
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification 
  • Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 
  • Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 
  • Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 
  • Publication of the 2024 Annual Financial Report 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}